公开(公告)号：US06479252B1

公开(公告)日：2002-11-12

申请号：US09724251

申请日：2000-11-28

Applicant: Emilio Barbera-Guillem ,  M. Bud Nelson

Inventor： Emilio Barbera-Guillem ,  M. Bud Nelson

IPC: C12P100

CPC classification number: C12M23/10 ,  C12M23/22 ,  C12M23/24 ,  C12M25/02 ,  C12M47/04 ,  C12N13/00

Abstract: Provided is a cell culture apparatus for culturing cells, and optionally, for performing magnetic separation of cells desired to be cultured. The cell culture apparatus preferably comprises a frame; two membranes, preferably each being gas permeable, which are securedly sealed in a leak-proof selaing to a frame in forming a culture chamber there-between; and at least one resealable aperture to allow substances to be introduced into, or withdrawn from, the culture chamber.

Abstract translation: 提供培养细胞的细胞培养装置，任选地，用于进行期望培养的细胞的磁分离。 细胞培养装置优选包括框架; 两个膜，优选每个都是可透气的，它们在形成其间的培养室的情况下被牢固地密封在防漏塞到框架中; 和至少一个可重新密封的孔，以允许物质被引入或从培养室中取出。

公开(公告)号：US06410309B1

公开(公告)日：2002-06-25

申请号：US09724153

申请日：2000-11-28

Applicant: Emilio Barbera-Guillem ,  M. Bud Nelson

Inventor： Emilio Barbera-Guillem ,  M. Bud Nelson

IPC: C12M112

CPC classification number: C12N13/00 ,  C12M23/10 ,  C12M23/22 ,  C12M23/24 ,  C12M23/58 ,  C12M25/02 ,  C12M47/04 ,  C12N15/87

Abstract: Provided is a cell culture apparatus for culturing cells, and optionally, for performing magnetic separation of cells desired to be cultured. The cell culture apparatus preferably comprises a frame; at least one gas permeable membrane securedly sealed in a leak-proof sealing to a frame and an opposing surface comprising a rigid surface in forming a culture chamber therebetween; and at least one resealable aperture to allow substances to be introduced into, or withdrawn from, the culture chamber.

Abstract translation: 提供培养细胞的细胞培养装置，任选地，用于进行期望培养的细胞的磁分离。 细胞培养装置优选包括框架; 将至少一个透气膜固定地密封在框架的防漏密封件中，以及包括刚性表面的相对表面，以在其间形成培养室; 和至少一个可重新密封的孔，以允许物质被引入或从培养室中取出。

公开(公告)号：US06245752B1

公开(公告)日：2001-06-12

申请号：US09299289

申请日：1999-04-26

Applicant: Emilio Barbera-Guillem ,  M. Bud Nelson

Inventor： Emilio Barbera-Guillem ,  M. Bud Nelson

IPC: A61K31715

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/385 ,  A61K47/56 ,  A61K47/646 ,  A61K47/6881 ,  A61K2039/6093 ,  Y02A50/41

Abstract: Methods and compositions are provided for tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression. The composition comprises a substantially non-immunogenic carrier molecule to which is linked carbohydrate chains containing a suppressive amount of a repeated, antigenic carbohydrate determinant derived from a shed antigen of interest. In a method of tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression, administered to an individual is a therapeutically effective amount of the composition which, when contacting the shed antigen-specific B cells, induces tolerization of the shed antigen-specific B cells.

Abstract translation: 提供了用于耐受参与免疫复合物介导的疾病进展的脱落抗原特异性B细胞的方法和组合物。 该组合物包含基本上非免疫原性的载体分子，其中连接的碳水化合物链含有抑制量的衍生自感兴趣的流感抗原的重复的抗原性碳水化合物决定簇。 在一种耐受涉及免疫复合物介导的疾病进展的脱落抗原特异性B细胞的方法中，施用于个体是组合物的治疗有效量，当与脱落的抗原特异性B细胞接触时，诱导棚的耐受性 抗原特异性B细胞。

公开(公告)号：US6074643A

公开(公告)日：2000-06-13

申请号：US882447

申请日：1997-06-26

Applicant: Emilio Barbera-Guillem

Inventor： Emilio Barbera-Guillem

IPC: A61K45/00 ,  A61K38/00 ,  A61K38/20 ,  A61K38/38 ,  A61K39/395 ,  A61K47/48 ,  A61P35/04 ,  C07K14/715 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  C12N9/02 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: C12N9/0071 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/38 ,  A61K47/48423 ,  A61K47/48561 ,  C07K16/2821 ,  C07K16/2866 ,  C12Q1/6886 ,  G01N33/5011 ,  G01N33/57488 ,  G01N33/57492 ,  G01N33/6869 ,  C07K2317/77 ,  G01N2333/55 ,  G01N2333/7051 ,  G01N2333/715 ,  Y10S436/827

Abstract: Provided for use in site-directed chemotherapy are compositions comprising chemotherapeutic agents targeted to either arrested metastatic cells via a cell-surface marker associated with metastasis; or are targeted to type 1 endothelial cells of the tissue comprising the organ site at which metastatic cells arrest such that (a) any arrested metastatic tumor cells are then exposed to the chemotherapeutic agent, and/or (b) the endothelial cells are altered thereby inhibiting the ability of the metastatic tumor cells to arrest, survive or proliferate in that site. Also provided are methods of site-directed chemotherapy of metastatic cells of non-lymphoid tumor origin. Site-directed chemotherapy comprises introducing a therapeutically effective amount of a chemotherapeutic agent directly into a vascular access of the organ having, or suspected of having, arrested metastatic cells thereby concentrating the therapy in the prometastatic territories of the treated organ.

Abstract translation: 提供用于定点化疗的组合物是包含化学治疗剂的组合物，其靶向通过与转移相关的细胞表面标志物停止转移细胞; 或靶向包含转移性细胞停滞的器官部位的组织的1型内皮细胞，使得（a）任何被阻止的转移性肿瘤细胞然后暴露于化学治疗剂，和/或（b）内皮细胞被改变 抑制转移性肿瘤细胞在该部位停滞，存活或增殖的能力。 还提供了非淋巴肿瘤来源的转移性细胞的定点化疗方法。 定点化疗包括将治疗有效量的化学治疗剂直接引入具有或怀疑具有转移细胞的器官的血管进入，从而将治疗集中在治疗的器官的前体区域中。